Future therapies for primary sclerosing cholangitis

Craig Lammert, Raj Vuppalanchi

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Primary sclerosing cholangitis (PSC) is a rare disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts leading to biliary strictures, parenchymal fibrosis, and subsequent progression to cirrhosis and liver failure. The disease is often associated with concomitant inflammatory bowel disease (IBD) and has varied phenotype and disease progression. PSC is an orphan disease, and currently there is no effective treatment other than liver transplantation. Fortunately, recent breakthroughs in the understanding of the pathogenesis of liver diseases have unraveled several new targets for treatment of PSC. In this chapter, we review the current understanding of the pathogenesis of PSC and the rationale behind the novel therapeutic interventions. The launch of additional trials will bring us a step closer to new treatments and an eventual cure for PSC.

Original languageEnglish (US)
Title of host publicationPrimary Sclerosing Cholangitis
Subtitle of host publicationCurrent Understanding, Management, and Future Developments
PublisherSpringer International Publishing
Pages153-166
Number of pages14
ISBN (Electronic)9783319409085
ISBN (Print)9783319409061
DOIs
StatePublished - Jan 1 2016

Fingerprint

Sclerosing Cholangitis
Fibrosis
Rare Diseases
Intrahepatic Bile Ducts
Therapeutics
Extrahepatic Bile Ducts
Liver Failure
Inflammatory Bowel Diseases
Liver Transplantation
Disease Progression
Liver Diseases
Pathologic Constriction
Inflammation
Phenotype

Keywords

  • Apical sodium-dependent bile acid transport inhibitors
  • Bicarbonate umbrella
  • Farnesoid X receptor
  • Fibroblast growth factor 19
  • Gut adhesion molecules
  • Gut-liver Axis
  • Lysyl oxidase-like
  • Toxic bile acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lammert, C., & Vuppalanchi, R. (2016). Future therapies for primary sclerosing cholangitis. In Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments (pp. 153-166). Springer International Publishing. https://doi.org/10.1007/978-3-319-40908-5_12

Future therapies for primary sclerosing cholangitis. / Lammert, Craig; Vuppalanchi, Raj.

Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Springer International Publishing, 2016. p. 153-166.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lammert, C & Vuppalanchi, R 2016, Future therapies for primary sclerosing cholangitis. in Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Springer International Publishing, pp. 153-166. https://doi.org/10.1007/978-3-319-40908-5_12
Lammert C, Vuppalanchi R. Future therapies for primary sclerosing cholangitis. In Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Springer International Publishing. 2016. p. 153-166 https://doi.org/10.1007/978-3-319-40908-5_12
Lammert, Craig ; Vuppalanchi, Raj. / Future therapies for primary sclerosing cholangitis. Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Developments. Springer International Publishing, 2016. pp. 153-166
@inbook{93672a286f4f423ea954de5d062e4df1,
title = "Future therapies for primary sclerosing cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a rare disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts leading to biliary strictures, parenchymal fibrosis, and subsequent progression to cirrhosis and liver failure. The disease is often associated with concomitant inflammatory bowel disease (IBD) and has varied phenotype and disease progression. PSC is an orphan disease, and currently there is no effective treatment other than liver transplantation. Fortunately, recent breakthroughs in the understanding of the pathogenesis of liver diseases have unraveled several new targets for treatment of PSC. In this chapter, we review the current understanding of the pathogenesis of PSC and the rationale behind the novel therapeutic interventions. The launch of additional trials will bring us a step closer to new treatments and an eventual cure for PSC.",
keywords = "Apical sodium-dependent bile acid transport inhibitors, Bicarbonate umbrella, Farnesoid X receptor, Fibroblast growth factor 19, Gut adhesion molecules, Gut-liver Axis, Lysyl oxidase-like, Toxic bile acids",
author = "Craig Lammert and Raj Vuppalanchi",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-40908-5_12",
language = "English (US)",
isbn = "9783319409061",
pages = "153--166",
booktitle = "Primary Sclerosing Cholangitis",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Future therapies for primary sclerosing cholangitis

AU - Lammert, Craig

AU - Vuppalanchi, Raj

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Primary sclerosing cholangitis (PSC) is a rare disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts leading to biliary strictures, parenchymal fibrosis, and subsequent progression to cirrhosis and liver failure. The disease is often associated with concomitant inflammatory bowel disease (IBD) and has varied phenotype and disease progression. PSC is an orphan disease, and currently there is no effective treatment other than liver transplantation. Fortunately, recent breakthroughs in the understanding of the pathogenesis of liver diseases have unraveled several new targets for treatment of PSC. In this chapter, we review the current understanding of the pathogenesis of PSC and the rationale behind the novel therapeutic interventions. The launch of additional trials will bring us a step closer to new treatments and an eventual cure for PSC.

AB - Primary sclerosing cholangitis (PSC) is a rare disease characterized by inflammation and fibrosis of the intra- and extrahepatic bile ducts leading to biliary strictures, parenchymal fibrosis, and subsequent progression to cirrhosis and liver failure. The disease is often associated with concomitant inflammatory bowel disease (IBD) and has varied phenotype and disease progression. PSC is an orphan disease, and currently there is no effective treatment other than liver transplantation. Fortunately, recent breakthroughs in the understanding of the pathogenesis of liver diseases have unraveled several new targets for treatment of PSC. In this chapter, we review the current understanding of the pathogenesis of PSC and the rationale behind the novel therapeutic interventions. The launch of additional trials will bring us a step closer to new treatments and an eventual cure for PSC.

KW - Apical sodium-dependent bile acid transport inhibitors

KW - Bicarbonate umbrella

KW - Farnesoid X receptor

KW - Fibroblast growth factor 19

KW - Gut adhesion molecules

KW - Gut-liver Axis

KW - Lysyl oxidase-like

KW - Toxic bile acids

UR - http://www.scopus.com/inward/record.url?scp=85018904485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018904485&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-40908-5_12

DO - 10.1007/978-3-319-40908-5_12

M3 - Chapter

AN - SCOPUS:85018904485

SN - 9783319409061

SP - 153

EP - 166

BT - Primary Sclerosing Cholangitis

PB - Springer International Publishing

ER -